Background Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons and α-synuclein accumulation. Despite extensive research, there remains a shortage of effective disease-modifying medicines, which is due in part to the failure to translate molecular insights into clinically useful models and diagnostics. Objectives This review will summarize recent developments in the PD pathophysiology and diagnostic, therapeutic and experimental models and will focus on the newer in vivo , in vitro and bioengineered in vivo platforms. Methods Recent studies on animal models, patient-induced pluripotent stem cell (iPSC) systems, three-dimensional (3D) bioprinting, neuroimaging, and biomarker discovery have been critically examined to determine their translational potential and limitations. Results Traditional animal models are effective at replicating dopaminergic degradation but fall short of fully replicating progressive and systemic elements of Parkinson's disease. iPSC-derived neurons and 3D-bioprinted constructs are more genetically specific and cellularly complex, allowing for patient-relevant modeling and medication screening. Advances in imaging and molecular biomarkers aid in earlier detection; nevertheless, no cross-validation or platform standards has been established. Conclusion Combining cellular, molecular, and bioengineered models with clinical diagnostics has the potential to improve translational accuracy and accelerate the development of disease-modifying treatments. A cross-platform system is critical for improving the predictive validity of preclinical studies in Parkinson's disease.
Kaushik Sunder (Mon,) studied this question.